Ishihara S, Horiguchi A, Miyakawa S, Endo I, Miyazaki M, Takada T. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016;23:149–57.
Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T. Biliary tract cancer treatment: 5,584 results from the biliary tract cancer statistics registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16:1–7.
Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469–74.
CAS PubMed PubMed Central Article Google Scholar
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
CAS PubMed Article Google Scholar
Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104:1211–6.
CAS PubMed PubMed Central Article Google Scholar
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16:967–78.
CAS PubMed PubMed Central Article Google Scholar
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950–8.
CAS PubMed Article Google Scholar
Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, et al. Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci. 2015;22:249–73.
Wang YF, Feng FL, Zhao XH, Ye ZX, Zeng HP, Li Z, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 2014;20:4085–92.
PubMed PubMed Central Article CAS Google Scholar
Liang B, Zhong L, He Q, Wang S, Pan Z, Wang T, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis. Med Sci Monit. 2015;21:3555–63.
CAS PubMed PubMed Central Article Google Scholar
Sheen-Chen SM, Sun CK, Liu YW, Eng HL, Ko SF, Kuo CH. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci. 2007;52:3140–2.
CAS PubMed Article Google Scholar
Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198:333–9.
CAS PubMed Article Google Scholar
Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997;94:11514–9.
CAS PubMed PubMed Central Article Google Scholar
Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006;66:4983–6.
CAS PubMed Article Google Scholar
Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10:2386–92.
CAS PubMed Article Google Scholar
Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442–6.
CAS PubMed Article Google Scholar
Wang X, Li Y, Tian H, Qi J, Li M, Fu C, et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2014;14:578.
PubMed PubMed Central Article CAS Google Scholar
Sugimoto M, Takagi T, Konno N, Suzuki R, Asama H, Watanabe K, et al. The efficacy of biliary and serum macrophage inhibitory cytokine-1 for diagnosing biliary tract cancer. Sci Rep. 2017;7:9198.
PubMed PubMed Central Article CAS Google Scholar
Babic A, Schnure N, Neupane NP, Zaman MM, Rifai N, Welch MW, et al. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol. 2018;9:145.
CAS PubMed PubMed Central Article Google Scholar
Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass. Cancer Biomark. 2018;21:505–11.
CAS PubMed Article Google Scholar
Yang Y, Yan S, Tian H, Bao Y. Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19–9 as a biomarker for diagnosis of pancreatic cancer: a PRISMA-compliant meta-analysis of diagnostic accuracy studies. Medicine (Baltimore). 2018;97: e9994.
O’Neill RS, Emmanuel S, Williams D, Stoita A. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort. World J Gastroenterol. 2020;26:1660–73.
CAS PubMed PubMed Central Article Google Scholar
Zhao Z, Zhang J, Yin L, Yang J, Zheng Y, Zhang M, et al. Upregulated GDF-15 expression facilitates pancreatic ductal adenocarcinoma progression through orphan receptor GFRAL. Aging (Albany NY). 2020;12:22564–81. https://doi.org/10.18632/aging.103830.
Guo F, Zhou Y, Guo H, Ren D, Jin X, Wu H. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Cell Death Discov. 2021;7:78.
PubMed PubMed Central Google Scholar
Ozkan H, Demirbaş S, Ibiş M, Akbal E, Köklü S. Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases. Pancreatology. 2011;11:295–300.
CAS PubMed Article Google Scholar
Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology. 2006;48:787–94.
CAS PubMed Article Google Scholar
Suzuki R, Okubo Y, Takagi T, Sugimoto M, Sato Y, Irie H, et al. The complement C3a–C3a receptor axis regulates epithelial-to-mesenchymal transition by activating the ERK pathway in pancreatic ductal adenocarcinoma. Anticancer Res. 2022;42:1207–15.
CAS PubMed Article Google Scholar
Maruyama M, Kobayashi N, Westerman KA, Sakaguchi M, Allain JE, Totsugawa T, et al. Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation. 2004;77:446–51.
CAS PubMed Article Google Scholar
Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol. 1989;25:503–10.
CAS PubMed Article Google Scholar
Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995;177:61–71.
CAS PubMed Article Google Scholar
Nagathihalli NS, Castellanos JA, VanSaun MN, Dai X, Ambrose M, Guo Q, et al. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget. 2016;7:65982–92.
PubMed PubMed Central Article Google Scholar
Sasahara A, Tominaga K, Nishimura T, Yano M, Kiyokawa E, Noguchi M, et al. An autocrine/paracrine circuit of growth differentiation factor (GDF) 15 has a role for maintenance of breast cancer stem-like cells. Oncotarget. 2017;8:24869–81.
PubMed PubMed Central Article Google Scholar
Zhao Z, Zhang J, Yin L, Yang J, Zheng Y, Zhang M, et al. Upregulated GDF-15 expression facilitates pancreatic ductal adenocarcinoma progression through orphan receptor GFRAL. Aging (Albany NY). 2020;12:22564–81.
Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Nozawa Y, et al. Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. Med Mol Morphol. 2018;51:176–85.
CAS PubMed Article Google Scholar
Sugimoto M, Abe K, Hayashi M, Takagi T, Suzuki R, Konno N, et al. The efficacy of serum cell death biomarkers for diagnosing biliary tract cancer. Sci Rep. 2018;8:16997.
PubMed PubMed Central Article CAS Google Scholar
Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: Guidelines of the International association of pancreatology. Pancreas. 2011;40:352–8.
留言 (0)